PMN Stock Forecast & Price Target

ProMIS Neurosciences Inc is advancing its Alzheimer’s candidate, PMN310, which has shown a favorable safety profile in clinical trials, notably with a significantly lower incidence of amyloid-related imaging abnormalities compared to marketed anti-amyloid antibodies. The ongoing Phase Ib PRECISE-AD study is over 85% enrolled, indicating robust progress toward key clinical milestones and reinforcing confidence in the therapy's potential. Furthermore, the Alzheimer’s market represents a substantial and rapidly expanding commercial opportunity, positioning ProMIS for future growth as it continues to develop innovative therapeutic solutions.

ProMIS Neurosciences reported a significant net loss of $11.6 million, equivalent to $0.24 per share in the third quarter of 2025, indicating ongoing financial challenges that may be exacerbated by potential partnership risks and the threat of market competition. The company's flagship candidate, PMN310, faces considerable hurdles, including demonstrating clinical efficacy and safety in Alzheimer's disease patients, with the risk of regulatory approval looming large amid the competitive landscape. Additionally, until ProMIS becomes cash flow positive, the risk of dilution through future fundraising efforts remains a substantial concern for investors.